Verition Fund Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Verition Fund Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.72M	Sell	44,776 -38,400	-46%	-$4.79M	0.04%	527
2025 Q4	$10.1M	Hold	83,176	–	–	0.04%	440
2025 Q3	$8.33M	Sell	83,176 -55,121	-40%	-$4.96M	0.03%	656
2025 Q2	$11.5M	Buy	138,297 +55,121	+66%	+$4.4M	0.05%	448
2025 Q1	$6.75M	Hold	83,176	–	–	0.03%	655
2024 Q4	$7.49M	Sell	83,176 -15,116	-15%	-$1.46M	0.03%	663
2024 Q3	$9.71M	Buy	98,292 +15,116	+18%	+$1.49M	0.05%	416
2024 Q2	$7.71M	Buy	83,176 +78,871	+1,832%	+$7.07M	0.04%	484
2024 Q1	$409K	Buy	+4,305	New	+$399K	﹤0.01%	2117
2023 Q4	–	Sell	-83,176	Closed	-$6.07M	–	2721
2023 Q3	$6.07M	Hold	83,176	–	–	0.07%	362
2023 Q2	$6.92M	Hold	83,176	–	–	0.09%	288
2023 Q1	$6.34M	Hold	83,176	–	–	0.09%	299
2022 Q4	$6.9M	Sell	83,176 -15,000	-15%	-$1.21M	0.11%	229
2022 Q3	$7.79M	Hold	98,176	–	–	0.09%	267
2022 Q2	$7.29M	Buy	98,176 +58,385	+147%	+$4.38M	0.14%	165
2022 Q1	$3.58M	Buy	39,791 +20,520	+106%	+$1.89M	0.04%	571
2021 Q4	$2.16M	Buy	19,271 +5,470	+40%	+$660K	0.02%	834
2021 Q3	$1.74M	Buy	+13,801	New	+$1.78M	0.02%	725
2021 Q2	–	Sell	-25,000	Closed	-$3.29M	–	2175
2021 Q1	$3.39M	Buy	+25,000	New	+$3.74M	0.04%	276
2014 Q1	–	Sell	-101,382	Closed	-$4.4M	–	657
2013 Q4	$4.4M	Buy	101,382 +85,917	+556%	+$3.56M	0.78%	19
2013 Q3	$666K	Sell	15,465 -60,795	-80%	-$2.46M	0.1%	161
2013 Q2	$2.65M	Buy	+76,260	New	+$2.68M	0.49%	32

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Verition Fund Management's XBI Position: Q1 2026 in Review

Verition Fund Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 46% in Q1 2026, selling an estimated $4.79M and leaving 44,776 shares worth $5.72M. The position accounts for 0.04% of the portfolio, ranked #527.

Verition Fund Management first reported a position in XBI in Q2 2013 and has held it in 22 quarters since. The position peaked at $11.5M in Q2 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Verition Fund Management held 44,776 shares of State Street SPDR S&P Biotech ETF worth $5.72M as of Q1 2026.
Verition Fund Management sold 38,400 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.79M.
State Street SPDR S&P Biotech ETF made up 0.04% of Verition Fund Management's portfolio in Q1 2026, its #527 holding.
Verition Fund Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 22 quarters since.
Verition Fund Management's State Street SPDR S&P Biotech ETF position peaked at $11.5M in Q2 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.